RTOG 0848: A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma

The purpose of this study is to:

  • Compare the effects, good and/or bad, of the drug erlotinib in combination with gemcitabine to gemcitabine alone for patients with pancreatic cancer that was removed by surgery to find out which is better.
  • Determine the effects, good and/or bad, of radiation for patients who remain disease-free after gemcitabine chemotherapy.
March 26, 2010
6100-CTO
Cancer - Gastro
Principal Investigator: Eleanor M Walker, MD

The purpose of this study is to:

  • Compare the effects, good and/or bad, of the drug erlotinib in combination with gemcitabine to gemcitabine alone for patients with pancreatic cancer that was removed by surgery to find out which is better.
  • Determine the effects, good and/or bad, of radiation for patients who remain disease-free after gemcitabine chemotherapy.
Histologic proof of primary head of pancreas invasive adenocarcinoma managed with a potentially curative resection (i.e., removal of all gross tumor) involving a classic pancreaticoduodenectomy (Whipple) or a pylorus preserving pancreaticoduodenectomy.
Open
Tiffany Pearce
(313) 916-1784